2015 Recommendations for the Management of Polymyalgia Rheumatica: A European League Against Rheumatism/American College of Rheumatology Collaborative Initiative

Arthritis and Rheumatology

Volumn 67, Issue 10, 2015, Pages 2569-2580

  Dejaco, Christian ^a,b   Singh, Yogesh P ^b   Perel, Pablo ^c   Hutchings, Andrew ^c   Camellino, Dario ^d   Mackie, Sarah ^e   Abril, Andy ^f   Bachta, Artur ^g   Balint, Peter ^h   Barraclough, Kevin ⁱ   Bianconi, Lina ^j   Buttgereit, Frank ^k   Carsons, Steven ^l   Ching, Daniel ^m   Cid, Maria ⁿ   Cimmino, Marco ^d   Diamantopoulos, Andreas ^o   Docken, William ^p   Duftner, Christina ^q   Fashanu, Billy ^b   Gilbert, Kate ^r   Hildreth, Pamela ^r   Hollywood, Jane ^b   Jayne, David ^s   Lima, Manuella ^t   Maharaj, Ajesh ^u   Mallen, Christian ^v   Martinez Taboada, Victor ^w   Maz, Mehrdad ^x   Merry, Steven ^y   Miller, Jean ^r   Mori, Shunsuke ^z   Neill, Lorna ^r   Nordborg, Elisabeth ^aa   Nott, Jennifer ^r   Padbury, Hannah ^r   Pease, Colin ^e   Salvarani, Carlo ^ab   Schirmer, Michael ^q   Schmidt, Wolfgang ^ac   Spiera, Robert ^ad   Tronnier, David ^y   Wagner, Alexandre ^ae   Whitlock, Madeline ^b   Matteson, Eric L ^af   Dasgupta, Bhaskar ^b   more..

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b SOUTHEND UNIVERSITY HOSPITAL   (United Kingdom)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^d UNIVERSITY OF GENOA   (Italy)

^e UNIVERSITY OF LEEDS   (United Kingdom)

^f MAYO CLINIC   (United States)

^g MILITARY INSTITUTE OF MEDICINE   (Poland)

^h NATIONAL INSTITUTE OF RHEUMATOLOGY AND PHYSIOTHERAPY   (Hungary)

ⁱ Hoyland House   (United Kingdom)

^j Bibbiano   (Italy)

^k CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^l STONY BROOK UNIVERSITY   (United States)

^m Timaru Hospital   (New Zealand)

ⁿ HOSPITAL CLÍNIC   (Spain)

^o Department of Rheumatology Hospital of Southern Norway Trust   (Norway)

^p BRIGHAM AND WOMEN S HOSPITAL   (United States)

^q INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^r Polymyalgia Rheumatica and Giant Cell Arteritis UK   (United Kingdom)

^s UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^t HOSPITAL UNIVERSITÁRIO PEDRO ERNESTO   (Brazil)

^u UNIVERSITY OF KWAZULU NATAL   (South Africa)

^v KEELE UNIVERSITY   (United Kingdom)

^w UNIVERSITY OF CANTABRIA   (Spain)

^x UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^y MAYO CLINIC   (United States)

^z Kumamoto Saishunsou National Hospital   (Japan)

^aa SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^ab Azienda Ospedaliera di Reggio Emilia   (Italy)

^ac MARTIN LUTHER KRANKENHAUS   (Germany)

^ad HOSPITAL FOR SPECIAL SURGERY   (United States)

^ae FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^af Mayo Clinic   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; CANAKINUMAB; CHINESE DRUG; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GLUCOCORTICOID; HERBACEOUS AGENT; HYDROXYCHLOROQUINE; METHOTREXATE; METHYLPREDNISOLONE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE; SECUKINUMAB; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; ANTIRHEUMATIC AGENT;

ADD ON THERAPY; ARTICLE; CLINICAL TRIAL (TOPIC); CORTICOSTEROID THERAPY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG MEGADOSE; EFFECTIVE DOSE (PHARMACOLOGY); HUMAN; KINESIOTHERAPY; LOW DRUG DOSE; MEDICAL SOCIETY; PATIENT CARE; PERSONALIZED MEDICINE; PHARMACEUTICAL EQUIVALENCE; PHYSIOTHERAPY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAXATION TRAINING; RHEUMATIC POLYMYALGIA; SHORT COURSE THERAPY; SINGLE DRUG DOSE; SYSTEMATIC REVIEW; CONSENSUS DEVELOPMENT; EUROPE; POLYMYALGIA RHEUMATICA; RISK FACTOR; UNITED STATES;

ANTIRHEUMATIC AGENTS; EUROPE; GLUCOCORTICOIDS; HUMANS; POLYMYALGIA RHEUMATICA; RISK FACTORS; UNITED STATES;

EID: 84941662697     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.39333     Document Type: Article

References (78)

1. Hutchings A, Hollywood J, Lamping DL, Pease CT, Chakravarty K, Silverman B, et al., Clinical outcomes, quality of life, and diagnostic uncertainty in the first year of polymyalgia rheumatica. Arthritis Rheum 2007; 57: 803-9.
2. Dejaco C, Duftner C, Dasgupta B, Matteson EL, Schirmer M,. Polymyalgia rheumatica and giant cell arteritis: management of two diseases of the elderly. Aging Health 2011; 7: 633-45.
3. Dasgupta B, Cimmino MA, Maradit Kremers H, Schmidt WA, Schirmer M, Salvarani C, et al., 2012 provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. Arthritis Rheum 2012; 64: 943-54.
4. Dasgupta B, Cimmino MA, Maradit-Kremers H, Schmidt WA, Schirmer M, Salvarani C, et al., 2012 provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. Ann Rheum Dis 2012; 71: 484-92.
5. Curtis JR, Westfall AO, Allison J, Bijlsma JW, Freeman A, George V, et al., Population-based assessment of adverse events associated with long-term glucocorticoid use. Arthritis Rheum 2006; 55: 420-5.
6. McDonough AK, Curtis JR, Saag KG., The epidemiology of glucocorticoid-associated adverse events. Curr Opin Rheumatol 2008; 20: 131-7.
7. Chuang TY, Hunder GG, Ilstrup DM, Kurland LT,. Polymyalgia rheumatica: a 10-year epidemiologic and clinical study. Ann Intern Med 1982; 97: 672-80.
8. Healey LA., Long-term follow-up of polymyalgia rheumatica: evidence for synovitis. Semin Arthritis Rheum 1984; 13: 322-8.
9. Bird HA, Esselinckx W, Dixon AS, Mowat AG, Wood PH,. An evaluation of criteria for polymyalgia rheumatica. Ann Rheum Dis 1979; 38: 434-9.
10. Jones JG, Hazleman BL., Prognosis and management of polymyalgia rheumatica. Ann Rheum Dis 1981; 40: 1-5.
11. Hamrin B., Polymyalgia arteritica. Acta Med Scand Suppl 1972; 533: 1-131.
12. Guyatt GH, Oxman AD, Schunemann HJ, Tugwell P, Knottnerus A,. GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology. J Clin Epidemiol 2011; 64: 380-2.
13. Brozek JL, Akl EA, Compalati E, Kreis J, Terracciano L, Fiocchi A, et al, for the GRADE Working Group. Grading quality of evidence and strength of recommendations in clinical practice guidelines: Part 3 of 3. The GRADE approach to developing recommendations. Allergy 2011; 66: 588-95.
14. Brozek JL, Akl EA, Jaeschke R, Lang DM, Bossuyt P, Glasziou P, et al, for the GRADE Working Group. Grading quality of evidence and strength of recommendations in clinical practice guidelines: Part 2 of 3. The GRADE approach to grading quality of evidence about diagnostic tests and strategies. Allergy 2009; 64: 1109-16.
15. Brozek JL, Akl EA, Alonso-Coello P, Lang D, Jaeschke R, Williams JW, et al, for the GRADE Working Group. Grading quality of evidence and strength of recommendations in clinical practice guidelines: Part 1 of 3. An overview of the GRADE approach and grading quality of evidence about interventions. Allergy 2009; 64: 669-77.
16. Dejaco C, Singh YP, Perel P, Hutchings A, Camellino D, Mackie S, et al., Current evidence for therapeutic interventions and prognostic factors in polymyalgia rheumatica: a systematic literature review informing the 2015 EULAR-ACR recommendations for the management of polymyalgia rheumatica. Ann Rheum Dis 2015. In press.
17. Balshem H, Helfand M, Schunemann HJ, Oxman AD, Kunz R, Brozek J, et al., GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol 2011; 64: 401-6.
18. Grade Working Group. GRADE homepage. http://www.gradeworkinggroup.org/index.htm.
19. Hayden JA, Cote P, Bombardier C., Evaluation of the quality of prognosis studies in systematic reviews. Ann Intern Med 2006; 144: 427-37.
20. Smolen JS, Landewe R, Breedveld FC, Dougados M, Emery P, Gaujoux-Viala C, et al., EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. [published erratum appears in Ann Rheum Dis 2011;70:1519]. Ann Rheum Dis 2010; 69: 964-75.
21. Smolen JS, Landewe R, Breedveld FC, Buch M, Burmester G, Dougados M, et al., EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014; 73: 492-509.
22. Gossec L, Smolen JS, Gaujoux-Viala C, Ash Z, Marzo-Ortega H, van der Heijde D, et al., European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis 2012; 71: 4-12.
23. Dasgupta B, Dolan AL, Panayi GS, Fernandes L,. An initially double-blind controlled 96 week trial of depot methylprednisolone against oral prednisolone in the treatment of polymyalgia rheumatica. Br J Rheumatol 1998; 37: 189-95.
24. Caporali R, Cimmino MA, Ferraccioli G, Gerli R, Klersy C, Salvarani C, et al, Systemic Vasculitis Study Group of the Italian Society for Rheumatology. Prednisone plus methotrexate for polymyalgia rheumatica: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 2004; 141: 493-500.
25. Van der Veen MJ, Dinant HJ, van Booma-Frankfort C, van Albada-Kuipers GA, Bijlsma JW,. Can methotrexate be used as a steroid sparing agent in the treatment of polymyalgia rheumatica and giant cell arteritis? [published erratum appears in Ann Rheum Dis 1996;55:563]. Ann Rheum Dis 1996; 55: 218-23.
26. Ferraccioli G, Salaffi F, De Vita S, Casatta L, Bartoli E,. Methotrexate in polymyalgia rheumatica: preliminary results of an open, randomized study. J Rheumatol 1996; 23: 624-8.
27. Nazarinia AM, Moghimi J, Toussi J., Efficacy of methotrexate in patients with polymyalgia rheumatica. Koomesh 2012; 14: 265-70.
28. Dasgupta B, Borg FA, Hassan N, Barraclough K, Bourke B, Fulcher J, et al, on behalf of the BSR and BHPR Standards, Guidelines and Audit Working Group. BSR and BHPR guidelines for the management of polymyalgia rheumatica. Rheumatology (Oxford) 2010; 49: 186-90.
29. NHG. NHG-Standaard Polymyalgia rheumatica en arteriitis temporalis. URL: https://www.nhg.org/standaarden/volledig/nhg-standaard-polymyalgia-rheumatica-en-arteriitis-temporalis.
30. Schmidt WA, Gromnica Ihle E., Polymyalgia rheumatica und Riesenzellarteriitis (Arteriitis temporalis). In:, Busse O, Fleig W, Mayet W, et al, eds. Rationelle Diagnostik und Therapie in der Inneren Medizin: Leitlinien-basierte Empfehlungen für die Praxis. Elsevier, 2011.
31. Kyle V, Hazleman BL., Treatment of polymyalgia rheumatica and giant cell arteritis. I. Steroid regimens in the first two months. Ann Rheum Dis 1989; 48: 658-61.
32. Duru N, van der Goes MC, Jacobs JW, Andrews T, Boers M, Buttgereit F, et al., EULAR evidence-based and consensus-based recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis 2013; 72: 1905-13.
33. Grossman JM, Gordon R, Ranganath VK, Deal C, Caplan L, Chen W, et al., American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis [published erratum appears in Arthritis Care Res (Hoboken) 2012;64:464]. Arthritis Care Res (Hoboken) 2010; 62: 1515-26.
34. Van der Goes MC, Jacobs JW, Boers M, Andrews T, Blom-Bakkers MA, Buttgereit F, et al., Monitoring adverse events of low-dose glucocorticoid therapy: EULAR recommendations for clinical trials and daily practice. Ann Rheum Dis 2010; 69: 1913-19.
35. Hoes JN, Jacobs JW, Boers M, Boumpas D, Buttgereit F, Caeyers N, et al., EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis 2007; 66: 1560-7.
36. Dolan AL, Moniz C, Dasgupta B, Li F, Mackintosh C, Todd P, et al., Effects of inflammation and treatment on bone turnover and bone mass in polymyalgia rheumatica. Arthritis Rheum 1997; 40: 2022-9.
37. Cimmino MA, Moggiana G, Montecucco C, Caporali R, Accardo S,. Long term treatment of polymyalgia rheumatica with deflazacort. Ann Rheum Dis 1994; 53: 331-3.
38. Cimmino MA, Parodi M, Caporali R, Montecucco C,. Is the course of steroid-treated polymyalgia rheumatica more severe in women? Ann N Y Acad Sci 2006; 1069: 315-21.
39. Ayoub WT, Franklin CM, Torretti D., Polymyalgia rheumatica. Duration of therapy and long-term outcome. Am J Med 1985; 79: 309-15.
40. Grant SD, Forsham PH, DiRaimondo VC., Suppression of 17-hydroxycorticosteroids in plasma and urine by single and divided doses of triamcinolone. N Engl J Med 1965; 273: 1115 -1 8.
41. Haus E, Sackett-Lundeen L, Smolensky MH., Rheumatoid arthritis: circadian rhythms in disease activity, signs and symptoms, and rationale for chronotherapy with corticosteroids and other medications. Bull NYU Hosp Jt Dis 2012; 70 Suppl 1: 3-10.
42. Angeli A., Circadian ACTH-adrenal rhythm in man. Chronobiologia 1974; 1 Suppl 1: 253-70.
43. Nichols T, Nugent CA, Tyler FH., Diurnal variation in suppression of adrenal function by glucocorticoids. J Clin Endocrinol Metab 1965; 25: 343-9.
44. Di Raimondo VC, Forsham PH., Some clinical implications of the spontaneous diurnal variation in adrenal cortical secretory activity. Am J Med 1956; 21: 321-3.
45. Diraimondo VC, Forsham PH., Pharmacophysiologic principles in the use of corticoids and adrenocorticotropin. Metabolism 1958; 7: 5-24.
46. DeAndrade JR., Pituitary-adrenocortical reserve during corticosteroid therapy: a report on the methopyrapone test in ten patients taking long-continued small doses. J Clin Endocrinol Metab 1964; 24: 261-2.
47. Barraclough K, Liddell WG, du Toit J, Foy C, Dasgupta B, Thomas M, et al., Polymyalgia rheumatica in primary care: a cohort study of the diagnostic criteria and outcome. Fam Pract 2008; 25: 328-33.
48. Maradit Kremers H, Reinalda MS, Crowson CS, Zinsmeister AR, Hunder GG, Gabriel SE,. Relapse in a population based cohort of patients with polymyalgia rheumatica. J Rheumatol 2005; 32: 65-73.
49. Salvarani C, Boiardi L, Mantovani V, Ranzi A, Cantini F, Olivieri I, et al., HLA-DRB1 alleles associated with polymyalgia rheumatica in northern Italy: correlation with disease severity. Ann Rheum Dis 1999; 58: 303-8.
50. Cantini F, Salvarani C, Olivieri I, Macchioni L, Ranzi A, Niccoli L, et al., Erythrocyte sedimentation rate and C-reactive protein in the evaluation of disease activity and severity in polymyalgia rheumatica: a prospective follow-up study. Semin Arthritis Rheum 2000; 30: 17-24.
51. Lee JH, Choi ST, Kim JS, Yoon BY, Kwok SK, Kim HS, et al., Clinical characteristics and prognostic factors for relapse in patients with polymyalgia rheumatica (PMR). Rheumatol Int 2013; 33: 1475-80.
52. Myklebust G, Gran JT., Prednisolone maintenance dose in relation to starting dose in the treatment of polymyalgia rheumatica and temporal arteritis. A prospective two-year study in 273 patients. Scand J Rheumatol 2001; 30: 260-7.
53. Gonzalez-Gay MA, Rodriguez-Valverde V, Blanco R, Fernandez-Sueiro JL, Armona J, Figueroa M, et al., Polymyalgia rheumatica without significantly increased erythrocyte sedimentation rate: a more benign syndrome. Arch Intern Med 1997; 157: 317-20.
54. Salvarani C, Cantini F, Macchioni P, Olivieri I, Niccoli L, Padula A, et al., Distal musculoskeletal manifestations in polymyalgia rheumatica: a prospective followup study. Arthritis Rheum 1998; 41: 1221-6.
55. Ramiro S, Gaujoux-Viala C, Nam JL, Smolen JS, Buch M, Gossec L, et al., Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis 2014; 73: 529-35.
56. Fu HZ., Clinical observation on effect of modified Yanghe Decoction combined with glycocorticoid for treatment of polymyalgia rheumatica. Zhongguo Zhong Xi Yi Jie He Za Zhi 2007; 27: 894-7.
57. Wang B, Zhang B, Wang H., Clinical observation about 18 cases of polymyalgia rheumatica by using Biqi capsule. China J Tradit Chinese Med Pharm 2009; 24: 596-8.
58. Hernandez-Rodriguez J, Cid MC, Lopez-Soto A, Espigol-Frigole G, Bosch X,. Treatment of polymyalgia rheumatica: a systematic review. Arch Intern Med 2009; 169: 1839-50.
59. Diamantopoulos AP, Hetland H, Myklebust G., Leflunomide as a corticosteroid-sparing agent in giant cell arteritis and polymyalgia rheumatica: a case series. Biomed Res Int 2013; 2013: 120638.
60. Adizie T, Christidis D, Dharmapaliah C, Borg F, Dasgupta B,. Efficacy and tolerability of leflunomide in difficult-to-treat polymyalgia rheumatica and giant cell arteritis: a case series. Int J Clin Pract 2012; 66: 906-9.
61. Al Rashidi A, Hegazi MO, Mohammad SA, Varghese A,. Effective control of polymyalgia rheumatica with tocilizumab. J Clin Rheumatol 2013; 19: 400-1.
62. Macchioni P, Boiardi L, Catanoso M, Pulsatelli L, Pipitone N, Meliconi R, et al., Tocilizumab for polymyalgia rheumatica: report of two cases and review of the literature. Semin Arthritis Rheum 2013; 43: 113-18.
63. Hagihara K, Kawase I, Tanaka T, Kishimoto T,. Tocilizumab ameliorates clinical symptoms in polymyalgia rheumatica. J Rheumatol 2010; 37: 1075-6.
64. De Silva M, Hazleman BL., Azathioprine in giant cell arteritis/polymyalgia rheumatica: a double-blind study. Ann Rheum Dis 1986; 45: 136-8.
65. Dejaco C, Duftner C, Cimmino MA, Dasgupta B, Salvarani C, Crowson CS, et al, and members of the International Work Group for PMR and GCA. Definition of remission and relapse in polymyalgia rheumatica: data from a literature search compared with a Delphi-based expert consensus. Ann Rheum Dis 2011; 70: 447-53.
66. Smolen JS, Aletaha D, Bijlsma JW, Breedveld FC, Boumpas D, Burmester G, et al, for the T2T Expert Committee. Treating rheumatoid arthritis to target: recommendations of an international task force [published erratum appears in Ann Rheum Dis 2011;70:1519]. Ann Rheum Dis 2010; 69: 631-7.
67. González-Gay MA, García-Porrúa C, Vázguez-Caruncho M, Dababneh A, Hajeer A, Ollier WE,. The spectrum of polymyalgia rheumatica in northwestern Spain: incidence and analysis of variables associated with relapse in a 10 year study. J Rheumatol 1999; 26: 1326-32.
68. Paulsen S., Polymyalgia rheumatica. Long term treatment with steroids. Ugeskr Laeger 1971; 133: 944-5.
69. Salvarani C, Cantini F, Niccoli L, Macchioni P, Consonni D, Bajocchi G, et al., Acute-phase reactants and the risk of relapse/recurrence in polymyalgia rheumatica: a prospective followup study. Arthritis Rheum 2005; 53: 33-8.
70. Caplanne D, Le Parc JM, Alexandre JA., lnterleukin-6 in clinical relapses of polymyalgia rheumatica and giant cell arteritis. Ann Rheum Dis 1996; 55: 403-4.
71. Kanemaru K, Nagura H, Ooyama T, Tomonaga M,. Report of 6 cases with polymyalgia rheumatica and a review of the literature. Nihon Ronen Igakkai Zasshi 1986; 23: 469-76. In Japanese.
72. Nagaoka S, Ohno M, Ohno S, et al., Long-term outcome for patients with polymyalgia rheumatica. Rinshou Ryumachi 2000; 12: 348-52. In Japanese.
73. Larrosa M, Gratacos J, Sala M., Polymyalgia rheumatica with low erythrocyte sedimentation rate at diagnosis. J Rheumatol 2000; 27: 1815 -1 6.
74. Proven A, Gabriel SE, O'Fallon WM, Hunder GG,. Polymyalgia rheumatica with low erythrocyte sedimentation rate at diagnosis. J Rheumatol 1999; 26: 1333-7.
75. Kimura M, Tokuda Y, Oshiawa H, Yoshida K, Utsunomiya M, Kobayashi T, et al., Clinical characteristics of patients with remitting seronegative symmetrical synovitis with pitting edema compared to patients with pure polymyalgia rheumatica. J Rheumatol 2012; 39: 148-53.
76. Ceccato F, Roverano SG, Papasidero S, Barrionuevo A, Rillo OL, Paira SO,. Peripheral musculoskeletal manifestations in polymyalgia rheumatica. J Clin Rheumatol 2006; 12: 167-71.
77. Mackie SL, Hensor EM, Haugeberg G, Bhakta B, Pease CT,. Can the prognosis of polymyalgia rheumatica be predicted at disease onset? Results from a 5-year prospective study. Rheumatology (Oxford) 2010; 49: 716-22.
78. Kanik KS, Bridgeford PH, Germain BF, Espinosa LR, Lowenstein M, Valeriano-Marcet J, et al., Polymyalgia rheumatica with a low erythrocyte sedimentation rate: comparison of 10 cases with 10 cases with high erythrocyte sedimentation rate. J Clin Rheumatol 1997; 3: 319-23.